RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
嵌合抗原受体 NK 细胞免疫治疗肿瘤的进展与挑战
英文原题：Advances and challenges in chimeric antigen receptor-natural killer cell immunotherapy for cancer.
查看英文原题
Advances and challenges in chimeric antigen receptor-natural killer cell immunotherapy for cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）自然杀伤（NK）细胞疗法已成为治疗血液系统恶性肿瘤和实体瘤的一种有前景策略。利用NK细胞的先天免疫特性，CAR-NK细胞疗法可能具有若干细胞治疗优势，包括可安全用于异基因治疗，且毒性风险较低。本文简要概述CAR-NK细胞疗法的最新进展及其仍面临的挑战。
展开英文摘要原文
Chimeric antigen receptor (CAR)-natural killer (NK)-cell therapy has emerged as a promising strategy in the treatment of haematological malignancies and solid cancers. Leveraging the innate immune properties of NK cells, CAR-NK-cell therapies offer potential advantages for cell therapy, including safety of use in the allogeneic setting and reduced risk of toxicity. This Nutshell provides an overview of the latest advancements in CAR-NK-cell therapy and the challenges that remain.
论文信息
- 作者
- Rafei H、Rezvani K
- 单位
- Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.United States
- 文献类型
- 综述
- 期刊
- British journal of haematology2025 Feb
- 原文标识
- PubMed 39622255 · DOI 10.1111/bjh.19939
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →